Alpha 2.0
Login Register
» Authors » Lila Zabaglo

Lila Zabaglo

Explore the profile of Lila Zabaglo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 750
Followers 0
Related Specialties
Oncology
Pathology
Cell Biology
Top 10 Co-Authors
Mitch Dowsett
Andrew Dodson
Margaret Hills
Janine Salter
Jack Cuzick
Lesley-Ann Martin
Ian Smith
Qiong Gao
Elizabeth Mallon
Judith M Bliss
Published In
Breast Cancer Res
J Clin Pathol
Clin Cancer Res
Cytometry A
J Natl Cancer Inst
Affiliations
Soon will be listed here.
Recent Articles
1.
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
Schuster E, Lopez-Knowles E, Alataki A, Zabaglo L, Folkerd E, Evans D, et al.
Nat Commun . 2023 Jul; 14(1):4017. PMID: 37419892
Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of...
2.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
Bliss J, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al.
Breast Cancer Res . 2023 Apr; 25(1):39. PMID: 37046348
Purpose: Ki67 assessed at diagnosis (Ki67) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki67) is associated with...
3.
A simple digital image analysis system for automated Ki67 assessment in primary breast cancer
Alataki A, Zabaglo L, Tovey H, Dodson A, Dowsett M
Histopathology . 2021 Feb; 79(2):200-209. PMID: 33590538
Aims: Ki67 is a well-established immunohistochemical marker associated with cell proliferation that has prognostic and predictive value in breast cancer. Quantitative evaluation of Ki67 is traditionally performed by assessing stained...
4.
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
Pancholi S, Leal M, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, et al.
Breast Cancer Res . 2020 Feb; 22(1):14. PMID: 32005287
After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni.
5.
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
Pancholi S, Leal M, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, et al.
Breast Cancer Res . 2019 Dec; 21(1):135. PMID: 31801615
Background: Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated...
6.
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
Leal M, Haynes B, Schuster E, Yeo B, Afentakis M, Zabaglo L, et al.
Clin Cancer Res . 2019 Sep; 25(24):7485-7496. PMID: 31548345
Purpose: To investigate the presence of mutations in primary estrogen-receptor-positive (ER) breast cancer treated with extended (>4 weeks) neoadjuvant (presurgical) aromatase inhibitor (NAI) therapy and to identify patients who may...
7.
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell G, Acar A, et al.
Clin Cancer Res . 2018 Jun; 24(19):4763-4770. PMID: 29891724
The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge...
8.
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration
Leung S, Nielsen T, Zabaglo L, Arun I, Badve S, Bane A, et al.
NPJ Breast Cancer . 2017 Jul; 2:16014. PMID: 28721378
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been...
9.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Bianchini G, Kiermaier A, Bianchi G, Im Y, Pienkowski T, Liu M, et al.
Breast Cancer Res . 2017 Feb; 19(1):16. PMID: 28183321
Background: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations...
10.
High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium
Abubakar M, Howat W, Daley F, Zabaglo L, McDuffus L, Blows F, et al.
J Pathol Clin Res . 2016 Aug; 2(3):138-53. PMID: 27499923
Automated methods are needed to facilitate high-throughput and reproducible scoring of Ki67 and other markers in breast cancer tissue microarrays (TMAs) in large-scale studies. To address this need, we developed...